XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for... It has been investigated for the treatment of hodgkin’s lymphoma.
- Mechanism
- Curator reviewed
XmAb™2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. XmAb™2513 has an XmAb™ Fc domain which increases its cytotoxic potency. XmAb™2513 recruits primary human immune cells to kill tumor cells in vitro models and is active in blocking tumor growth in rodent models. [Xencor Website]
- Primary indication
- Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).Curator reviewed
- Code names
- XMAB-2513
Resolves to
What you can answer from here — as of April 23, 2025
Which drugs share a target with XmAb 2513, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account